For example, the use mRNA-based vaccines or repeat arrays of short immunogenic peptides as were used in a recent malaria vaccine targeting the circumsporozoite protein (Jelínková et al., 2021) could potentially bypass the need to make full-length or partial versions of the HAP2/GCS1 protein which can be difficult using conventional recombinant protein expression platforms. The gene discussed is MOGS; the disease is malaria.